Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04677959 · ClinicalTrials.gov registry record · Phase 4

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma

A Phase 4 study of Asthma, sponsored by Teva Branded Pharmaceutical Products R&D.

Completed
Registry status
Phase 4
Development phase
427
Enrollment target
20
Study locations

NCT04677959: Completed Phase 4 study of Asthma, sponsored by Teva Branded Pharmaceutical Products R&D.

NCT04677959 is a Phase 4 study of Asthma that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 427 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04677959, a Phase 4 study of Asthma, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.

COMPLETED
Registry status
Phase 4
Development phase
427 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to demonstrate the effectiveness of the Digital System (DS) in improving asthma control compared to the Standard of Care (SoC) group. The secondary objective is to describe the asthma management actions by investigational center health care providers (iHCPs) for all participants in both groups, to evaluate short-acting beta2 agonist (SABA) usage and the number of SABA-free days in the DS group, to evaluate adherence patterns to maintenance treatment (FS eMDPI) in the DS group, to assess behavioral correlates of responsiveness to digital health technology among participants for all participants in both groups, to evaluate work productivity and activity impairment in asthma participants in both groups, to assess the usability and acceptability of the DS by participants in the DS group and the investigational center personnel, and to evaluate the safety of FS eMDPI and Albuterol eMDPI.

Primary Outcome

A well-controlled asthma was defined as an Asthma Control Test (ACT) score of greater than or equal to 20. Clinically important improvement in asthma control was defined by an increase of at least 3 ACT units from baseline. The ACT was a simple, participant-completed tool used for the assessment of overall asthma control. The ACT included 5 items that assessed daytime and nighttime asthma symptoms, use of reliever medication, and impact of asthma on daily functioning. Each item in the ACT was sc

Conditions Studied

Interventions

  • DRUG Albuterol
  • DRUG Fluticasone propionate/salmeterol (FS)
  • DRUG Standard of Care Asthma Medication
  • DRUG Standard of Care Rescue Medication

Study Locations (20)

Florida

  • Teva Investigational Site 14943 - Aventura
  • Teva Investigational Site 14969 - Boynton Beach
  • Teva Investigational Site 14978 - Cutler Bay
  • Teva Investigational Site 14955 - Fort Lauderdale
  • Teva Investigational Site 14984 - Hialeah
  • Teva Investigational Site 14979 - Hialeah
  • Teva Investigational Site 14953 - Miami
  • Teva Investigational Site 14975 - Miami
  • Teva Investigational Site 14944 - Miami
  • Teva Investigational Site 14970 - Miami
  • Teva Investigational Site 14960 - Miami Lakes
  • Teva Investigational Site 14981 - Sarasota
  • Teva Investigational Site 14951 - Tallahassee

California

  • Teva Investigational Site 14974 - Fountain Valley
  • Teva Investigational Site 14982 - Los Angeles
  • Teva Investigational Site 14945 - San Diego
  • Teva Investigational Site 14946 - San Diego

Colorado

  • Teva Investigational Site 14966 - Colorado Springs
  • Teva Investigational Site 14962 - Wheat Ridge

Arizona

  • Teva Investigational Site 14971 - Phoenix

Trial Details

FieldValue
Enrollment Target 427 participants
Start Date 2021-02-16
Est. Completion 2022-03-10
Phase Phase 4

What the finished NCT04677959 record still lists

NCT04677959 is an interventional study that assigns participants to a tested intervention. The registered 427 participants enrollment target is mid-sized for trials with a published cap, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (73% lower).

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 4 interventions - of which Albuterol is the first listed.

NCT04677959 names 20 study sites across 4 states, led by Florida, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT04677959 about?

NCT04677959 is a clinical study titled "A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma". The primary objective of this study is to demonstrate the effectiveness of the Digital System (DS) in improving asthma control compared to the Standard of Care (SoC) group. The secondary objective is to describe the asthma management actions by investigational center health care providers (iHCPs) f...

What is the current status of trial NCT04677959?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 427 participants. The study started on 2021-02-16. Estimated completion is 2022-03-10.

What conditions does trial NCT04677959 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT04677959?

The interventions under investigation include: Albuterol (DRUG), Fluticasone propionate/salmeterol (FS) (DRUG), Standard of Care Asthma Medication (DRUG), Standard of Care Rescue Medication (DRUG).

Who is sponsoring clinical trial NCT04677959?

This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04677959 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04677959's enrollment target sits among peer trials

427 87th of 374 higher than 288 of 374 other Asthma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05566431 · 428 participants · NA

    Benchmark Evidence Led by Latin America: Trial of Intracranial Pressure - Pediatrics

  • NCT05646316 · 428 participants · Phase 3

    Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer

  • NCT05797610 · 428 participants · Phase 3

    A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

  • NCT06073626 · 428 participants · NA

    Addressing Genomic Disparities in Cancer Survivors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04677959, the US trial registry maintained by the National Library of Medicine. NCT04677959 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.